The truth behind medication for anxiety

A variety of medications have been found helpful in treating anxiety disorders, but none of them work for every person. While selective serotonin reuptake inhibitors (SSRIs) andserotonin-norepinephrine reuptake inhibitors (SNRIs) are considered the first-line treatment for many anxiety disorders,2 each individual needs to work with his or her physician to identify the best approach.

What are You Using Medication for?

An important issue you should discuss is whether you’re using medication for long-term change or short-term relief. Some medications aren’t intended to be used for more than several weeks. Other medications must be taken for a long time to maintain their results.4 And when some antianxiety medications are discontinued, problems with anxiety often return. Some medications cannot be stopped abruptly and must be tapered off to prevent severe withdrawal symptoms. In some cases, such as with the long-term use of benzodiazepines, anxiety and other problems may actually worsen after the medication is discontinued.5 So, it’s important to discuss:

  • How long a medication can be safely used
  • When and if you are expected to stop taking it
  • What will happen when you stop taking the medication

Another important consideration is the effect of medication on therapy. Some medications have been shown to increase or decrease the effectiveness of various therapeutic approaches, like Cognitive Behavioral Therapy.1 The right combination of medication and treatment can also vary depending on what phase of treatment you’re in. If you are in therapy, or plan to seek therapy, be sure to discuss all of this with your doctor (and/or therapist) to ensure you achieve the most beneficial outcome.

Medication Side Effects

No discussion of medication with your doctor is complete unless you address side effects. Side effects are unintended adverse consequences associated with taking medication. In the case of antianxiety medications, side effects can range from an upset stomach to confusion, and from muscle weakness to sexual dysfunction. There are logical reasons for side effects. First, keep in mind that brain functions rely on neurotransmitters, chemicals that allow neurons to communicate with each other. The brain and the rest of the body uses a limited number of neurotransmitters in multiple neurological processes. Just as you can use baking soda for a variety of purposes (for leavening, as a cleaning agent or toothpaste, to deodorize your refrigerator, and so on), the human body uses most neurotransmitters in a variety of different systems.

Therefore, medications designed to influence a neurotransmitter’s activity in one set of brain circuits may also have a side effect of influencing completely unrelated processes. Consider serotonin, a neurotransmitter often thought to be involved in various areas of the brain that create anxiety. Medications used to increase serotonin levels in the brain may also affect intestinal processes because serotonin plays a key role in coordinating muscle contraction in the intestines. This results in side effects that can include constipation or diarrhea.

Because it’s very difficult to impact levels of a neurotransmitter in a specific location without influencing other parts of the nervous system, side effects are expected when people take medications for anxiety. Furthermore, levels of one neurotransmitter in the brain may shift in response to changes in levels of other neurotransmitters. Therefore, it’s difficult to use medication to make one change in the brain without affecting other systems.

Finally, because no two brains or bodies are exactly alike, medications frequently have different effects on different people. So a medication that’s helpful for one person may have only negative effects for another person. No one can predict the response a specific individual will have to a specific anti-anxiety medication. Under a doctor’s supervision, a person may have to try a few different medications before finding the one that works best.

Furthermore, new side effects can develop after long-term use of a medication. The brain is a responsive and adaptive system, and it adjusts to changes in its chemistry in complex and sometimes unexpected ways. It can change its structure or reduce its production of specific chemicals in response to the continued presence of certain medications. Long-term impacts on the brain other than those intended for treatment can occur. However, we know very little about these effects because they’re rarely studied. Pharmaceutical companies that design and evaluate medications tend to focus primarily on their short-term benefits and safety, and clinical trials of the effects of a medication rarely last more than one year.

Categories of Antianxiety Medications

As we noted, the most commonly prescribed antianxiety medications fall into four categories:

Each kind of medication attempts to reduce anxiety in a different way and has different influences on the process of rewiring the brain. You will be more likely to benefit from a medication if you know what to expect from it and use it in a way that promotes the changes you hope to produce.

Review Your Medications

So, before you read the next article in this series, it will be helpful if you know what kind of medication you are taking or considering taking. On a blank piece of paper, list the medications you’ve taken, or are considering taking, to treat your anxiety and identify what category each falls into. Use RxList and MedlinePlus to help you categorize your medication. If you have already tried medications, describe the effects each medication has had on you—both positive and negative. The next installments of this series will explain to you what to expect and what not to expect from each category of medication.

Other articles in this series include:

Part 1: Medication As Part Of Your Anxiety Treatment

Part 3: SSRI Fact Sheet

Part 4: SNRI Fact Sheet

Posted in Anxiety | Leave a comment

Research observes effects of mental health issues on telomeres and aging

It has become widely thought among healthcare professionals and the public alike that mental health affects physical well-being. New research suggests that depression and anxiety may speed up the aging process, leading to the development of chronic disease. Here, I discuss my research on the link between depression, anxiety, and short telomere length – a condition wherein the protective caps at the ends of cells are shortened to the point wherein those cells no longer divide.

Linking Telomere Length to Aging and Disease

For the past ten years, I have been interested in identifying the various mechanisms by which mental health problems, such as depression and anxiety, influence the development of chronic physical health problems, such as cardiovascular disease. My most recent work in this area examined associations between depression, anxiety, and telomere length, a potential biological mechanism linking mental health problems to morbidity and mortality.

Telomeres are the protective caps at the ends of chromosomes that shorten each time a cell divides. Eventually, critically shortened telomeres trigger cellular senescence, when cells essentially get old and stop dividing. Therefore, telomere length is thought to be a biological marker of aging. In support of this theory, a growing number of studies have shown that shorter telomere length is associated with diseases of aging, including cardiovascular disease, type 2 diabetes, dementia, and cancer, independent of chronological age. In addition, some studies have found that shorter telomere length predicts increased risk of death.

Women with Anxiety Found to Have Shorter Telomere Length

To examine the hypothesis that anxiety and depression are associated with shorter telomeres, my coauthors and I used data collected between 1999 and 2002 from the National Health and Nutrition Examination Survey (NHANES).1 In all, our study included 1,164 white, African-American, and Mexican-American participants between the ages of 20 and 39, some of whom had major depression, Generalized Anxiety Disorder, or panic disorder in the past year. Among female study participants, those with anxiety or panic disorder had shorter telomeres than similar women who reported no symptoms of anxiety. No association was found between anxiety disorders and telomere length among men.

More Severe Depression Could Be Linked to Shorter Telomeres in Young Adults

In the full sample, no association was found between major depression and telomere length. Among current antidepressant users, however, those with major depression had shorter telomeres than those who reported no symptoms of depression. A small amount (4.5%) of respondents reported current antidepressant use. Antidepressant use was more frequent among participants with depression or anxiety, but was also reported by those with no depressive or anxious symptoms. We found no association between current antidepressant use and telomere length in the full sample, only for those who had depression in the past year despite current use of antidepressant medications.

Further Research on Telomere Length and Mental Health is Needed

Due to the fact that the study is observational, the conclusion that mental health problems cause short telomeres remains tentative. Longer term studies in the same individuals could help determine whether changes in mental health are associated with changes in telomere length over time, providing stronger evidence for a causal association. I hope that our study will encourage research on the biological mechanisms linking mental health disorders to physical health problems, and inspire health care providers, policymakers, and the public to recognize the importance of mental health problems for overall health and well-being.

Research on the link between mental and physical health tells us that our minds and bodies are connected. If you or someone you know are experiencing symptoms of depression or anxiety, and you are worried about the physical health consequences, talk to your doctor about treatment options.

Date of original publication: June 15, 2015
Updated on: February 03, 2016
Posted in News & updates | Leave a comment

Improving COPD by treating anxiety and depression

Chronic Obstructive Pulmonary Disease (COPD) causes difficulty breathing and progressively gets worse. COPD is also known as emphysema or chronic bronchitis.Past studies report that COPD patients often also suffer from anxiety and depression due to symptoms such as chronic coughing and difficulty breathing, which can interrupt daily activities. In hopes of creating better treatment plans for those with COPD, a study seen in the September 2014 issue of Egyptian Journal of Chest Diseases and Tuberculosis examines the efficacy of treating anxiety and depression to improve the quality of life for COPD patients.

Incorporating Antidepressants and Anxiolytics Into COPD Therapy

The study examined 33 males and 17 females with severe COPD who were also diagnosed with depression and anxiety. Depression was assessed using the Montgomery and Asberg Depression Rating Scale (MADRS). The MADRS indicates if the patient has non-existing, mild, moderate, or severe levels of depression. Similar to the MADRS, the Hamilton Anxiety (HAM-A) measured levels of anxiety. The scales revealed that:

  • 32 patients suffered from depression alone
  • 5 patients suffered from anxiety alone
  • 13 patients had both anxiety and depression

The 50 subjects were then split into two groups of 25: group I would be treated for anxiety and depression, while group II served as the control. Group I was treated with antidepressants and anxiolytics for three months. Antidepressants are prescribed medications that are commonly used to treat moderate to severe depression. Common antidepressants include Celexa and Prozac. To treat anxiety, anxiolytics such as Xanax and Klonopin are often prescribed. For this study, group I took 20mg of Fluoxetine daily. This particular drug was chosen because it serves as both an antidepressant and anxiolytic.

Medicated Treatment Shows Significant Reduction in Depression and Anxiety

At the end of the three months, the participants were reassessed with the MADRS and HAM-A. Those who received medicated treatment for their anxiety and depression showed significantly lower scores on both scales, suggesting that their mental health had improved. Osama M. Momtaz, the head researcher of this study, recommends physicians treat anxiety and depression in COPD because “it is associated with a significant improvement in pulmonary physiological parameters.” In other words, decreasing anxiety and depression also increases physical health, thus improving a COPD patient’s quality of life.

Posted in News & updates | Leave a comment

A less traditional class of drugs could offer effective treatment for PTSD

Post-traumatic Stress Disorder (PTSD) is a serious anxiety disorder that results from exposure to a traumatic experience or from witnessing a life-threatening event such as violence, abuse, accident, war, disaster, or any situation that seriously threatens the integrity of a person. PTSD is known to be common among veterans, but is also highly prevalent in women. The affliction is currently a very serious burden in the U.S., with high associated mortality rates and healthcare costs.

A spate of treatments are available for those with PTSD, ranging from mental psychotherapy to antidepressants. There’s also exciting news in the area of PTSD treatment: the healthcare community has its eye on a different class of drugs that offers the potential to be highly effective at treating PTSD symptoms.

A Possible New Treatment Method for PTSD Sufferers

Research on PTSD is steadily increasing year by year, which has drawn me to investigate current and potential treatments for the affliction. The first line of treatment for the disorder generally consists of psychotherapy, such as cognitive therapy, exposure therapy, stress inoculation training, and pharmacotherapy with antidepressants, specifically selective serotonin reuptake inhibitors (SSRIs) such as Sertraline and Paroxetine.

Atypical antipsychotics (AAs), which have traditionally been used to treat schizophrenia, are in a different class of drugs from antidepressants, the common standard for PTSD medication. AAs can affect several neurotransmitter systems which have been proven to be involved with the psychophysiology of PTSD. AAs have gotten a lot of attention from the scientific community, but current data proving its efficacy for PTSD is still insufficient. Thus, my team and I set out to conduct a meta-analysis in order to further clarify the effectiveness of AA therapies on PTSD.

Atypical Antipsychotics Reduce PTSD Symptoms

Our meta-analysis included the findings from 455 patients in eight studies: 231 were allocated to AA groups that received medication, and 224 were allocated to placebo groups. The results indicated that AAs were more effective than a placebo in treating PTSD patients. When the effects of pharmacotherapy were compared with placebo treatment, we found significant decreases in PTSD symptoms.

The Side Effects of AAs are Comparable to a Placebo

People with PTSD frequently have to be concerned about how to manage the side effects of their medication, which can often include muscle spasms and other movement disorders. In addition, the metabolic side-effects of AAs, which can lead to weight gain and diabetes, are also a critical concern for long-term use.

In order to analyze these possible drawbacks, we conducted a meta-analysis on dropout rates. Surprisingly, the results showed no statistical difference between AAs and placebo on acceptability and side effects. This finding may be explained by the low doses of AAs used to treat PTSD: somewhere between one-third and one-half of the dosage used to treat schizophrenia is given to people with PTSD.

Pharmacotherapy Shows Strong Potential in PTSD Treatment

AAs could be an effective new choice for treating PTSD, offering the benefits of reduced side effects when compared to other current mediations. We hope that our research and the search for better treatments will allow more people who suffer from PTSD to find greater peace of mind.

Date of original publication: June 18, 2015
Updated on: February 10, 2016
Posted in News & updates | Leave a comment

These antidepressants may have limited effectiveness

Doctors often prescribe antidepressants, such as paroxetine (Paxil), fluvoxamine (Luvox), or sertraline (Zoloft), for the treatment of anxiety. Many antidepressants fall into the category of medications called selective serotonin reuptake inhibitors (SSRIs) and are approved for the treatment of anxiety disorders, such as Generalized Anxiety Disorder and panic disorder. However, new research indicates that SSRIs may provide little benefit in relieving symptoms of anxiety.

Our group of researchers at Wayne State University and the Harvard Medical School analyzed all clinical trials examining the benefit of the SSRI paroxetine compared to placebos in the treatment of Generalized Anxiety Disorder (GAD) or panic disorder across all trials sponsored by the drug’s manufacturer, GlaxoSmithKline (GSK). According to GSK, 12 clinical trials have been done, although four of them were not published in medical journals. We examined how much improvement individuals in these studies made on the Hamilton Rating Scale for Anxiety, one of the most frequently used measures of anxiety symptoms. The scale has a maximum score of 56 points. Higher scores represent more severe symptoms of anxiety. At the beginning of the trials, the average scores in each sample were between 19 and 26 points.

We found that during these relatively short trials of 8 to 12 weeks, the average improvement for individuals given paroxetine was 11.1 points, and 8.8 points for individuals given placebo. That is, the drug provided an average benefit over placebo of only 2.3 points on a 56-point scale, and the improvement for individuals given placebo matched 79 percent of the improvement for individuals given the drug. The benefit of the drug was lower in the unpublished trials, indicating that the published studies may have overestimated the drug’s effectiveness.

Our study is the first large-scale analysis of an SSRI compared to placebo in the treatment of anxiety; previous analyses have focused on the treatment of depression. Although our study is limited to only one medication, previous studies have found that all second-generation antidepressants have comparable effectiveness in treating depression.1 Thus, our results may generalize to other antidepressants, although further studies are necessary to support this proposition.

Antidepressants’ Benefits may not Outweigh Risks

Overall, the benefit provided by paroxetine in the treatment of anxiety is small. As a result, the benefit may not be substantial enough to warrant a recommendation for them to be used as a first-line treatment in clinical practice, given the side effects associated with SSRIs.

One common side effect of SSRIs is treatment-induced sexual dysfunction. Sexual dysfunction is seen as a side effect in approximately 70 percent of patients taking paroxetine, and most other SSRIs produce similar rates.2 Other side effects include drowsiness, insomnia, and long-term weight gain. Rare but more severe risks include increased suicidal thoughts in children and young adults and serotonin syndrome, a life-threatening adverse reaction to the medication. Furthermore, patients are much more likely to disclose negative side effects on a questionnaire rather than tell their doctor about it, which is the traditional method of obtaining side effect data in clinical trials.3Thus, published findings may underestimate the true level of adverse effects. In addition to side effects while taking antidepressants, there are also withdrawal effects following discontinuation of the medicationthat may trigger a relapse of symptoms.4 These withdrawal effects may help to explain why most people stay on antidepressants for two years or longer.5

But Treating Anxiety is Within the Reach of Many

Many people report experiencing a great deal of benefit from antidepressants for their anxiety. However, because individuals given placebos experience a similar benefit that was almost 80 percent as effective, most of their improvement is not due to the specific ingredients in the drugs. Notably, people who receive placebos fare much better than those given no treatment at all, such as individuals on waiting lists to be enrolled in the clinical trials.6 These findings indicate that taking action to enroll in a treatment program and participating in some type of intervention may be therapeutic in itself. The belief that an individual is receiving treatment (even if that treatment is as simple as a daily sugar pill) is a major component of symptom relief. The specific chemicals in the drugs may be less responsible for the improvement, and these drugs come with risks.

Psychotherapy is another treatment option for individuals suffering from anxiety. It does not carry the antidepressant-related risks such as the side effects and withdrawal effects and a recent study found that 75 percent of patients prefer therapy over psychiatric medications.7 Short-term studies have shown comparable effectiveness between antidepressants and psychotherapy. However, longer comparisons show a clear superiority for psychotherapy over antidepressants.8,9 Psychotherapy, when conducted properly, is aimed at not only providing support and relieving symptoms, but also at helping individuals to develop and practice skills to prevent future occurrences of similar symptoms. This skill development is absent with medication intervention and may be part of the reason for psychotherapy’s long-term superiority as a treatment.

Our study demonstrates that paroxetine provides only a modest benefit in treating anxiety. We believe that this benefit is not large enough to justify SSRI use for anxiety, given the risks associated with the medication. For individuals looking to take control of their anxiety, it is important to understand the limitations of antidepressants and to know that other options are available. Talk with your doctor about psychotherapy and other treatment options that could be well suited to you and your symptoms.

Posted in News & updates | Leave a comment